查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲非侵入性产前检测 (NIPT) 市场：按方法、按平台、按最终用户、按应用、按国家 - 分析和预测 (2023-2033)
市场调查报告书
商品编码
1594218

欧洲非侵入性产前检测 (NIPT) 市场：按方法、按平台、按最终用户、按应用、按国家 - 分析和预测 (2023-2033)

Europe Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Platform, End User, Application, and Country - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 78 Pages | 商品交期: 1-5个工作天内

价格

2023年，欧洲非侵入性产前检测（NIPT）市场规模达8.592亿美元。预计到 2033 年，该市场将达到 32.306 亿美元，2023-2033 年预测期间复合年增长率为 14.16%。欧洲 NIPT 市场的主要动力是有利指南的引入、将筛检程序纳入报销政策、技术的持续进步、整个全部区域商业机会的扩大以及对非侵入性检测方法的日益偏好。

主要市场统计数据
预测期 2023-2033
2023年评估 8.592 亿美元
2033年预测 32.306 亿美元
复合年增长率 14.16%

近年来，由于基因组技术的进步以及对更安全、更准确的产前筛检技术的需求不断增长，欧洲的非侵入性产前检测（NIPT）市场显着增长。这种突破性的方法被称为 NIPT，透过分析母亲血液中的胎儿游离 DNA 来检测染色体异常，例如帕陶氏症候群、爱德华兹症候群和唐氏症。由于 NIPT 是非侵入性的，因此它没有羊膜穿刺术等传统诊断技术的风险，因此受到准父母和医疗保健相关人员的青睐。

有利的法律规范、患者和医疗保健专业人员知识的增加以及 NIPT 纳入公共和私人医疗保健系统都有助于市场成长。许多欧洲国家的报销规定进一步推动了 NIPT 的普及，特别是在产前护理基础设施完善的地区。

市场主要参与企业专注于提高 NIPT 服务的可负担性、可近性和准确性的技术进步。此外，妊娠晚期和母亲老化的趋势增加了对可靠产前筛检方法的需求。因此，欧洲 NIPT 市场预计将稳步扩大，有助于改善全部区域的孕产妇和胎儿医疗保健结果，并促进明智的决策。

该报告考察了欧洲无创产前检测 (NIPT) 市场，提供了市场概况、方法、平台、最终用户、应用、国家和进入市场的公司的概况等。

目录

执行摘要

第一章 市场

  • 趋势：当前和未来的影响评估
  • 供应链概览
  • 研究发展回顾
  • 监管状况
  • 赎回场景
  • 市场动态概览

第二章 区域

  • 促进因素和抑制因素
  • 区域概况
  • 欧洲

第三章市场－竞争基准化分析与公司概况

  • 竞争格局
    • F. Hoffmann-La Roche Ltd
    • CENTOGENE NV
    • Yourgene Health
    • Eurofins Scientific SE

第四章调查方法

Product Code: BHL2393SS

Introduction to Europe Non-Invasive Prenatal Testing (NIPT) Market

The Europe NIPT market was valued at $859.2 million in 2023 and is expected to reach $3,230.6 million by 2033, registering a CAGR of 14.16% during the forecast period 2023-2033. The European NIPT market is primarily driven by the implementation of favorable guidelines, the inclusion of screening procedures in reimbursement policies, ongoing advancements in technology, expanding commercial opportunities across the region, and the growing preference for non-invasive testing methods.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$859.2 Million
2033 Forecast$3,230.6 Million
CAGR14.16%

The market for non-invasive prenatal testing (NIPT) in Europe has grown significantly in recent years due to the development of genomic technologies and the increased need for prenatal screening techniques that are safer and more accurate. The ground-breaking method known as NIPT looks for chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome by analyzing cell-free fetal DNA in the mother's bloodstream. It is a preferred choice for pregnant parents and medical professionals because of its non-invasive nature, which removes the hazards connected to conventional diagnostic techniques like amniocentesis.

Favorable regulatory frameworks, growing patient and healthcare professional knowledge, and the incorporation of NIPT into both public and private healthcare systems all contribute to the market's growth. Its popularity has been further accelerated by reimbursement regulations in a number of European nations, especially in areas with established prenatal care infrastructure.

The market's major players are concentrating on technology advancements to improve the NIPT services' affordability, accessibility, and accuracy. Furthermore, the necessity for trustworthy prenatal screening methods has increased due to the tendency of late pregnancies and the aging of mothers. Consequently, the NIPT market in Europe is expected to increase steadily, contributing to better maternal and fetal healthcare outcomes throughout the area and facilitating informed decision-making.

Market Segmentation:

Segmentation 1: by Application

  • Trisomy Detection
  • Microdeletion Detection
  • Sex Chromosome Aneuploidy Detection
  • Others

Segmentation 2: by End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

Segmentation 3: by Platform

  • NGS
  • PCR
  • Others

Segmentation 4: by Method

  • cfDNA
  • FCMB

Segmentation 5: by Country

  • France
  • Germany
  • Italy
  • Spain
  • U.K.
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Europe NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • F. Hoffmann-La Roche Ltd
  • CENTOGENE N.V.
  • Yourgene Health
  • Eurofins Scientific SE

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
    • 1.1.2 Expanding Applications in NIPT Products
  • 1.2 Supply Chain Overview
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Scenario in the U.K.
    • 1.4.2 Regulatory Scenario in Germany
    • 1.4.3 Regulatory Scenario in France
    • 1.4.4 Regulatory Scenario in Spain
    • 1.4.5 Regulatory Scenario in Italy
    • 1.4.6 Regulatory Scenario in the Netherlands
  • 1.5 Reimbursement Scenario
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 High Incidence of Genetic Disorders
      • 1.6.1.2 Rising Maternal Age
      • 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
      • 1.6.1.4 Increased Emphasis on Early Detection and Prevention
    • 1.6.2 Market Restraints
      • 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
      • 1.6.2.2 Lack of Awareness Regarding NIPT
      • 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)

2 Regions

  • 2.1 Drivers and Restraints
  • 2.2 Regional Summary
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 France
    • 2.3.7 Germany
    • 2.3.8 U.K.
    • 2.3.9 Spain
    • 2.3.10 Italy
    • 2.3.11 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 F. Hoffmann-La Roche Ltd
      • 3.1.1.1 Overview
      • 3.1.1.2 Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
    • 3.1.2 CENTOGENE N.V.
      • 3.1.2.1 Overview
      • 3.1.2.2 Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View
    • 3.1.3 Yourgene Health
      • 3.1.3.1 Overview
      • 3.1.3.2 Product Portfolio
      • 3.1.3.3 Top Competitors
      • 3.1.3.4 Target Customers
      • 3.1.3.5 Key Personnel
      • 3.1.3.6 Analyst View
    • 3.1.4 Eurofins Scientific SE
      • 3.1.4.1 Overview
      • 3.1.4.2 Product Portfolio
      • 3.1.4.3 Top Competitors
      • 3.1.4.4 Target Customers
      • 3.1.4.5 Key Personnel
      • 3.1.4.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022, 2026, and 2033
  • Figure 2: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 4: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022, 2026, and 2033
  • Figure 5: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022, 2026, and 2033
  • Figure 6: Non-Invasive Prenatal Testing Market, Recent Developments, 2023
  • Figure 7: Supply Chain of NIPT Market
  • Figure 8: NIPT Market, Patent Analysis, (by Country), January 2020-December 2023
  • Figure 9: NIPT Market, Patent Analysis, (by Year), January 2020-December 2023
  • Figure 10: Reimbursement Scenario in Major Countries of the Europe NIPT Market
  • Figure 11: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 12: Births with Trisomies per 100,000 Live Births in Europe Region, 2000-2021
  • Figure 13: Age of Mother at Childbirth over the Years
  • Figure 14: Reimbursement Scenario in Major Countries
  • Figure 15: Number of Tests Processed by Natera, Inc., 2018-2020
  • Figure 16: Positives from Data of 75,000 NIPT Tests Showing False Positives
  • Figure 17: Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 18: Europe Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 19: France Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 20: France Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 21: Germany Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 22: Germany Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 23: U.K. Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 24: U.K. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 25: Spain Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 26: Spain Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 27: Italy Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 28: Italy Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 29: Rest-of-Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 30: Rest-of-Europe Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 31: Share of Strategic Initiatives
  • Figure 32: Data Triangulation
  • Figure 33: Top-Down and Bottom-Up
  • Figure 34: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Non-Invasive Prenatal Testing Market, Opportunities
  • Table 3: Key Companies' Partnerships and Alliances
  • Table 4: NIPT Tests in the NIPT Market and their Corresponding Applications
  • Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
  • Table 6: Non-Invasive Prenatal Testing Market (by Region), Thousands Units, 2022-2033
  • Table 7: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022-2033
  • Table 8: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 9: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 10: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 11: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 12: France Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 13: France Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 14: France Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 15: France Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 16: Germany Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 17: Germany Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 18: Germany Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 19: Germany Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 20: U.K. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 21: U.K. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 22: U.K. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 23: U.K. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 24: Spain Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 25: Spain Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 26: Spain Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 27: Spain Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 28: Italy Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 29: Italy Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 30: Italy Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 31: Italy Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 32: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 33: Rest-of-Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 34: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 35: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 36: Market Share (2022)